Diabetes Archives

cytotools medday stock black friday drop phase III fail

News and Trends 4 Dec 2015

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

A shocking Black Friday for these two Biotechs: Both CytoTools (Germany) and MedDay (France) phase III trials in chronic disease flopped massively, and stocks dropped as much as 85% in one day… Multiple Sclerosis Headliner, MedDay’s MD1003, has flopped in its phase III trial after failing to meet its primary endpoint. This is a disastrous […]

December 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 26 Nov 2015

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

Ablynx – the Belgian Nanobody biotech (which uses monoclonal antibodies of Alpacas) has entered a new and exclusive partnership with the Danish Novo Nordisk on a mysterious disease… Ablynx are famously well connected in the biotech industry, with many huge pharmas licensing out their Alpaca-nanobody tech. Partnerships include AbbVie (Immunology), Boehringer Ingelheim, Genzyme (Multiple Sclerosis/CNS), […]

November 26, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 12 Oct 2015

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Monellin chain B is an artificial sweetener initially mistaken for a carbohydrate. It has since been established to actually be a natural protein based sweetner which is fairly unstable. iSweetch from the University of Naples has used E. Coli to engineer a more stable version of the protein to revolutionize the artificial sweetner industry. Monellin […]

October 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn’t changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech startups worldwide) has just published positive phase III results of its implantable device aiming at changing how type 2 diabetes are treated. November 2014: I thought […]

September 18, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy. Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand […]

September 16, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) enzymes which are expressed by the NOX-gene family (NOX 1-5). NOX enzymes generate reactive oxidative species (ROS) which if overproduced, can cause […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 4 Sep 2015

Gut bacteria growth time can cause disease?

A method of profiling bacterial growth time in the gut’s microbiome has been shown to be a rudimentary diagnostic tool for IBS and diabetes type II. A research team came together from the labs of Dr Elinav and Professor Segal to investigate at the Weizmann Institute of Science, Israel. The millions of bacteria living within our […]

September 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 2 Sep 2015

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

Novo Nordisk has acquired two small Indiana based research Biotechs, Calibrium and MB2, as part of its strategy to establish itself in the US as a major Diabetes research giant. Novo Nordisk, a global endocrine research giant hailing from Copenhagen, Denmark, has plans to acquire two smaller, privately held research companies into its conglomeration. Focusing […]

September 2, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 31 Aug 2015

When Tech and Biotech merge, Google and Sanofi partner up to revolutionize Diabetes Management

Taking care of diabetes is still far too complex currently. In future, Sanofi and Google will jointly take care of this problem, hoping to ease the life of millions of people with type 1 and type 2 diabetes. When it comes to transforming our diabetes treatment technology, Google loves European Pharmas. Together with Novartis, it […]

August 31, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 26 Aug 2015

Ouch! Novo Nordisk fails in Phase III

Novo Nordisk joins UCB and gets knocked down by its drug’s final clinical trial. Liraglutide, the already approved adjunct therapy for people with type 2 diabetes won’t reach out to type 1 diabetes. Novo Nordisk can look at a 90-year long history of improving the lives of diabetes patients. However, the phase IIIa trial that […]

August 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 3 Aug 2015

Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

Olivier Brandicourt, new CEO of Sanofi since last April, has been interviewed by EuroBusiness Media on the company’s last results. The successor of Chris Viehbacher took the opportunity to show the good results made by its Biotech pipeline. Genzyme, the rare diseases arm of Sanofi, was an important growth driver again this quarter. Total sales of the Rare […]

August 3, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 7 Jul 2015

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Novo Nordisk cancels its collaboration deal with Zosano Pharma. The diabetes drug semaglutine won’t be delivered with the microneedle patch technology, developed from the latter. Zosano’s patch technology uses thin titanium microprojections to deliver drugs that cannot permeate the outer layer of the skin. According to Zosano, the system was tested on 400 patients in […]

July 7, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Diabetes

Black Friday Ruin as TWO Biotechs Fail in Phase III Trials

Ablynx Top Trumps: Adding Danish Diabetes Giant Novo Nordisk to its Biotech Deck

A Sweet idea from Napoli; An Italian start-up will renovate the Artificial Sweetener market

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

Gut bacteria growth time can cause disease?

Novo-expansion! US Based Calibrium and MB2 snapped up by Danish Diabetes Giant

When Tech and Biotech merge, Google and Sanofi partner up to revolutionize Diabetes Management

Ouch! Novo Nordisk fails in Phase III

Sanofi’s CEO, Olivier Brandicourt takes stock of its Biotech pipeline

Novo Nordisk abandons Zosano’s drug delivery technology for diabetes treatment

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!